Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR: Long-acting Cabotegravir + Rilpivirine in HIV-1
NCT03639311Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of cabotegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With HIV-RNA >=50 Copies/mL at Month 12. Started Sep 2018; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03639311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639311.